Vaxart, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Vaxart, Inc. (VXRT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $24.85 per share for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2019-05-09
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2019-03-31 was $24.85.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2016-09-30 was $2.59, a 96.58% decline year-over-year.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2015-09-30 was $75.81, a 1630.82% increase year-over-year.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2014-09-30 was $4.38.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2018 was $34.64, a 188.67% increase from fiscal 2017.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2017 was $12.00.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2016 was $12.77, a 4.49% decline from fiscal 2015.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2015 was $13.37, a 61.09% decline from fiscal 2014.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2019-03-31 | $24.85 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | $34.64 10-K · filed 2019-02-06 | |||
| 2018-09-30 | $35.11 10-Q · filed 2018-11-13 | |||
| 2017-12-31 | $12.00 10-K · filed 2019-02-06 | |||
| 2016-09-30 | $2.59 10-Q · filed 2016-11-08 | |||
| 2016-06-30 | $12.77 10-K · filed 2017-09-01 | |||
| 2015-09-30 | $75.81 10-Q · filed 2015-11-06 | |||
| 2015-06-30 | $13.37 10-K · filed 2016-09-13 | |||
| 2015-03-31 | $10.00 10-Q · filed 2015-05-08 | |||
| 2014-12-31 | $9.73 10-Q · filed 2015-02-06 | |||
| 2014-09-30 | $4.38 10-Q · filed 2014-11-07 | |||
| 2014-06-30 | $34.36 10-K · filed 2014-09-30 | |||
| 2014-03-31 | $36.18 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |